

Samuel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5482530/samuel-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225
papers

18,533
citations

47
h-index

135
g-index

244
ext. papers

22,844
ext. citations

8.4
avg, IF

6.85
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 225 | Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.. <i>Thrombosis Research</i> , 2022 , 211, 63-69 | 8.2 | |
| 224 | Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and knee Replacement (PEPPER): the PEPPER trial protocol.. <i>BMJ Open</i> , 2022 , 12, e060000 | 3 | 2 |
| 223 | Women@ representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment.. <i>Contemporary Clinical Trials</i> , 2022 , 115, 106714 | 2.3 | 1 |
| 222 | Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.. <i>Thrombosis Research</i> , 2022 , 214, 122-131 | 8.2 | 0 |
| 221 | Ultrasound-facilitated, catheter-directed thrombolysis versus anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study.. <i>American Heart Journal</i> , 2022 , 251, 43-43 | 4.9 | 3 |
| 220 | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1635-1654 | 15.1 | 9 |
| 219 | Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. <i>Vascular Medicine</i> , 2021 , 26, 662-669 | 3.3 | 0 |
| 218 | Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021 , 20, 103-107 | 1.3 | 0 |
| 217 | Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 158-160 | 5.1 | |
| 216 | Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 281-290 | 5.1 | 1 |
| 215 | PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. <i>BMJ Open</i> , 2021 , 11, e041845 | 3 | 0 |
| 214 | Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 22-29 | 5.1 | |
| 213 | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1903-1921 | 15.1 | 84 |
| 212 | Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1620-1630 | 27.4 | 235 |
| 211 | Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2021 , | 7 | 21 |
| 210 | Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 1023-1031 | 5.1 | 0 |
| 209 | Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , | 5.3 | 1 |

| | | | |
|-----|---|------|----|
| 208 | Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. <i>Journal of the American Heart Association</i> , 2021 , 10, e021117 | 6 | 1 |
| 207 | Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 408-411 | 15.1 | 24 |
| 206 | Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 405-412 | 5.1 | 1 |
| 205 | Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 33-42 | 35.1 | 31 |
| 204 | Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , 2021 , 26, e8-e16 | 5.7 | 10 |
| 203 | Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 561-570 | 5.1 | |
| 202 | Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021 , 5, e24-e34 | 3.4 | 6 |
| 201 | Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211037920 | 3.3 | |
| 200 | Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes - Double trouble when vascular medicine emergencies meet. <i>Vascular Medicine</i> , 2021 , 1358863X211029695 | 3.3 | |
| 199 | The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021 , 203, 155-162 | 8.2 | 1 |
| 198 | Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. <i>American Journal of Medicine</i> , 2021 , 134, 1419-1423 | 2.4 | |
| 197 | Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1 | 5.1 | 0 |
| 196 | Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2021 , 14, e012347 | 3.9 | 1 |
| 195 | Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3080-3089 | 15.4 | 3 |
| 194 | "Acute Management of High- and Intermediate-Risk Pulmonary Embolism in Children: A Review". <i>Chest</i> , 2021 , | 5.3 | 2 |
| 193 | Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021 , 10, e021467 | 6 | 2 |
| 192 | Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3031-3043 | 15.4 | 1 |
| 191 | Association of ABO blood group type with cardiovascular events in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 584-586 | 5.1 | 3 |

| | | | |
|-----|---|------|-----|
| 190 | Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , 2020 , 41, 1086-1096 | 9.5 | 19 |
| 189 | Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020 , 19, 178-186 | 1.3 | 0 |
| 188 | Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020 , 133 Suppl 1, 1-27 | 2.4 | 7 |
| 187 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024 | 7 | 147 |
| 186 | Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism: A SEATTLE II Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008747 | 6 | 3 |
| 185 | Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 924-936 | 7 | 5 |
| 184 | External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1381-1389 | 15.4 | 3 |
| 183 | Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020 , 186, 78-79 | 8.2 | 2 |
| 182 | Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , 2020 , 133, 936-945 | 2.4 | 8 |
| 181 | Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020 , 196, 382-394 | 8.2 | 43 |
| 180 | Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 908-918 | 5.3 | 4 |
| 179 | Selection Bias, Orthopaedic Style: Knowing What We Don't Know About Aspirin. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102, 631-633 | 5.6 | 5 |
| 178 | Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020 , 8, 8-23.e18 | 3.2 | 27 |
| 177 | New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 301-309 | 6.4 | 15 |
| 176 | Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <i>American Journal of Cardiology</i> , 2020 , 133, 175-178 | 3 | 3 |
| 175 | Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2060-2072 | 15.1 | 119 |
| 174 | Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020 , 3, e2022886 | 10.4 | 5 |
| 173 | Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 214-219 | 5.1 | 4 |

| | | | |
|-----|--|------|------|
| 172 | 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020 , 41, 543-603 | 9.5 | 1043 |
| 171 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973 | 15.1 | 1682 |
| 170 | Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020 , 190, 555-561 | 4.5 | 14 |
| 169 | Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619876030 | 3.3 | 12 |
| 168 | Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. <i>European Heart Journal</i> , 2019 , 40, 1515-1517 | 9.5 | 2 |
| 167 | Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 633-644 | 7 | 22 |
| 166 | Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1694-1706 | 15.4 | 17 |
| 165 | Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1365-1372 | 7 | 18 |
| 164 | Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019 , 3, e103-e108 | 2.7 | 1 |
| 163 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 45 | 5.3 | 17 |
| 162 | How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 2 |
| 161 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2089-2098 | 15.4 | 4 |
| 160 | Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 574-576 | 27.4 | 43 |
| 159 | Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1675-1685 | 7 | 15 |
| 158 | Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1686-1694 | 7.4 | 3 |
| 157 | Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , 2019 , 132, 1133-1141 | 12.4 | 49 |
| 156 | Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019 , 7, 118-126 | 0.9 | |
| 155 | Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. <i>Vascular Medicine</i> , 2019 , 24, 442-451 | 3.3 | 18 |

| | | | |
|-----|--|------|-----|
| 154 | Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619880008 | 3.3 | 4 |
| 153 | Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019 , 139, 1234-1236 | 16.7 | 4 |
| 152 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019 , 45, 477-487 | 14.5 | 12 |
| 151 | Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e009903 | 3.9 | 7 |
| 150 | Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 319-327 | 7 | 43 |
| 149 | Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019 , 380, 752-762 | 59.2 | 538 |
| 148 | Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 331-335 | 5.1 | 2 |
| 147 | Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019 , 179, 263-265 | 11.5 | 6 |
| 146 | Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. <i>Circulation</i> , 2019 , 139, 1162-1173 | 16.7 | 104 |
| 145 | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019 , 94, 21-28 | 7.1 | 28 |
| 144 | Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018 , 131, 972.e1-972.e7 | 2.4 | 15 |
| 143 | Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation</i> , 2018 , 137, 21-31 | 16.7 | 25 |
| 142 | Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 274-280 | 5.1 | 19 |
| 141 | Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 257-263 | 5.1 | 4 |
| 140 | Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018 , 198, 84-90 | 4.9 | 16 |
| 139 | A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018 , 6, 54-61 | 0.9 | 1 |
| 138 | Pharmacomechanical Therapy for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2018 , 378, 1752-1753 | 59.2 | 0 |
| 137 | Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , 2018 , 33, 21-25 | 4 | 5 |

| | | | |
|-----|--|------|-----|
| 136 | Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018 , 2, e16-e24 | 2.7 | 6 |
| 135 | Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , 2018 , 131, 1408-1417 | 2.4 | 21 |
| 134 | Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , 2018 , 268, 137-142 | 3.2 | 16 |
| 133 | A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1401-1410 | 5 | 147 |
| 132 | Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. <i>TH Open</i> , 2018 , 2, e49-e53 | 2.7 | |
| 131 | Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 1-8 | 5.1 | 14 |
| 130 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2046-2052 | 7 | 28 |
| 129 | LetQ Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , 2018 , 138, 2591-2593 | 16.7 | 12 |
| 128 | Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018 , 2, e33-e38 | 2.7 | 6 |
| 127 | Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , 2018 , 2, e229-e232 | 2.7 | 2 |
| 126 | Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , 2017 , 25, 54-62 | 1.3 | 4 |
| 125 | Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 5 |
| 124 | Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , 2017 , 22, 44-50 | 3.3 | 24 |
| 123 | Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER, RE-COVERII, and RE-MEDY. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 484-489 | 5.1 | 3 |
| 122 | Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017 , 7, e014579 | 3 | 22 |
| 121 | Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , 2017 , 22, 324-330 | 3.3 | 3 |
| 120 | Evaluation of a Device Combining an Inferior VenaCava Filter and a Central Venous CatheterForPreventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 1248-1254 | 2.4 | 17 |
| 119 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. <i>American Heart Journal</i> , 2017 , 185, 93-100 | 4.9 | 43 |

| | | | |
|-----|--|------|-----|
| 118 | RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 415-427 | 7 | 11 |
| 117 | Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017 , 1, e82-e91 | 2.7 | 6 |
| 116 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. <i>Pharmaceutical Statistics</i> , 2017 , 16, 445-450 | 1 | 6 |
| 115 | N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 457-465 | 5.1 | 8 |
| 114 | Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1587-1597 | 15.1 | 94 |
| 113 | Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 30 |
| 112 | The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017 , 1, e56-e65 | 2.7 | 62 |
| 111 | Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017 , 377, 2240-2252 | 59.2 | 363 |
| 110 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). <i>Circulation</i> , 2017 , 135, 648-655 | 16.7 | 46 |
| 109 | Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2389-2395 | 7 | 18 |
| 108 | Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2045-2052 | 7 | 29 |
| 107 | NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1317-1325 | 7 | 14 |
| 106 | More than an anticoagulant: Do heparins have direct anti-inflammatory effects?. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 437-444 | 7 | 121 |
| 105 | Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016 , 21, 227-32 | 2.6 | 9 |
| 104 | Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER I, RE-COVER II, and RE-MEDY. <i>Vascular Medicine</i> , 2016 , 21, 506-514 | 3.3 | 43 |
| 103 | Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 714-21 | 7 | 13 |
| 102 | Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , 2016 , 21, 361-8 | 3.3 | 13 |
| 101 | Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. <i>Vascular Medicine</i> , 2016 , 21, 400-7 | 3.3 | 35 |

| | | | |
|-----|--|------|-----|
| 100 | Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016 , 27, 787-94 | 2.4 | 19 |
| 99 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016 , 129, 1198-1204 | 2.4 | 101 |
| 98 | Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism: Medicare Hospitalizations From 1999 to 2010. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1027-1035 | 15.1 | 47 |
| 97 | Warfarin and Vascular Calcification. <i>American Journal of Medicine</i> , 2016 , 129, 635.e1-4 | 2.4 | 55 |
| 96 | Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism. <i>Vascular Medicine</i> , 2016 , 21, 47-52 | 3.3 | 18 |
| 95 | The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial. <i>Blood</i> , 2016 , 128, 3824-3824 | 2.2 | |
| 94 | Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016 , 375, 534-44 | 59.2 | 286 |
| 93 | Syncope (Fainting). <i>Circulation</i> , 2016 , 133, e600-2 | 16.7 | 10 |
| 92 | Women and Heart Attacks. <i>Circulation</i> , 2016 , 133, e428-9 | 16.7 | 2 |
| 91 | North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016 , 129, S1-S29 | 2.4 | 19 |
| 90 | Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , 2015 , 100, 1245-51; discussion 1251-2 | 2.7 | 84 |
| 89 | Cardiology Patient Page. Obstructive Sleep Apnea. <i>Circulation</i> , 2015 , 132, e114-6 | 16.7 | 2 |
| 88 | A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1382-1392 | 5 | 427 |
| 87 | Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. <i>Hospital Practice (1995)</i> , 2015 , 43, 249-57 | 2.2 | 16 |
| 86 | Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , 2015 , 169, 186-7 | 4.9 | 9 |
| 85 | A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , 2015 , e52761 | 1.6 | 3 |
| 84 | Venous thromboembolism: "... an ounce of prevention is worth a pound of cure". <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1174-5 | 7 | |
| 83 | Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , 2015 , 175, 1112-7 | 11.5 | 58 |

| | | | |
|----|---|------|------|
| 82 | Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis. <i>American Journal of Medicine</i> , 2015 , 128, 747-59.e2 | 2.4 | 138 |
| 81 | Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ¹ and RE-COVER II ² <i>Blood</i> , 2015 , 126, 4730-4730 | 2.2 | |
| 80 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. <i>European Heart Journal</i> , 2014 , 35, 1836-43 | 9.5 | 15 |
| 79 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. <i>Circulation</i> , 2014 , 129, 764-72 | 16.7 | 678 |
| 78 | Cardiology Patient Page: inflammation and myocardial infarction. <i>Circulation</i> , 2014 , 130, e334-6 | 16.7 | 8 |
| 77 | The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014 , 167, 335-41 | 4.9 | 69 |
| 76 | Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY ¹ <i>Blood</i> , 2014 , 124, 1544-1544 | 2.2 | 7 |
| 75 | Post-Hoc Analysis of RE-MEDY ¹ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism. <i>Blood</i> , 2014 , 124, 4270-4270 | 2.2 | 2 |
| 74 | Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER ¹ and RE-COVER II. <i>Blood</i> , 2014 , 124, 594-594 | 2.2 | 7 |
| 73 | Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 371-4 | 5.1 | 2 |
| 72 | Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis. <i>Hospital Practice (1995)</i> , 2013 , 41, 123-31 | 2.2 | 2 |
| 71 | Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013 , 122, 1136-1136 | 2.2 | 4 |
| 70 | Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013 , 122, 212-212 | 2.2 | 10 |
| 69 | Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , 2013 , 122, 2375-2375 ⁹ | 2.2 | 9 |
| 68 | Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013 , 122, 582-582 | 2.2 | 12 |
| 67 | Pulmonary embolism and deep vein thrombosis. <i>Lancet, The</i> , 2012 , 379, 1835-46 | 40 | 605 |
| 66 | Venous thromboembolism: epidemiology and magnitude of the problem. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 235-42 | 4.2 | 145 |
| 65 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e419S-e496S | 5.3 | 2575 |

| | | | |
|----|--|------|------|
| 64 | Axial and reformatted four-chamber right ventricle-to-left ventricle diameter ratios on pulmonary CT angiography as predictors of death after acute pulmonary embolism. <i>American Journal of Roentgenology</i> , 2012 , 198, 1353-60 | 5.4 | 56 |
| 63 | Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etxilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , 2012 , 120, 21-21 | 2.2 | 8 |
| 62 | Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. <i>New England Journal of Medicine</i> , 2011 , 365, 2167-77 | 59.2 | 423 |
| 61 | Peripherally inserted central catheters: bigger is not necessarily better. <i>Chest</i> , 2011 , 140, 6-7 | 5.3 | 6 |
| 60 | Optimal duration of anticoagulation after venous thromboembolism. <i>Circulation</i> , 2011 , 123, 664-7 | 16.7 | 25 |
| 59 | Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. <i>Circulation</i> , 2011 , 123, 1788-830 | 16.7 | 1448 |
| 58 | A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , 2011 , 118, 205-205 | 2.2 | 41 |
| 57 | Eradication of hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 1089-92 | | 10 |
| 56 | European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?. <i>Clinical Chemistry</i> , 2010 , 56, 1544-6 | 5.5 | 6 |
| 55 | Risk factors for venous thromboembolism. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1-7 | 15.1 | 377 |
| 54 | Diagnosis. Magnetic resonance angiography and venography were sensitive but had poor technical adequacy for diagnosing pulmonary embolism. <i>Annals of Internal Medicine</i> , 2010 , 153, JC1-12 | 8 | 1 |
| 53 | Pulmonary embolism in Black Americans. <i>American Journal of Hematology</i> , 2010 , 85, 465-6 | 7.1 | 1 |
| 52 | Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. <i>International Journal of Cardiovascular Imaging</i> , 2009 , 25, 101-7 | 2.5 | 46 |
| 51 | Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. <i>American Heart Journal</i> , 2009 , 157, 1064-73 | 4.9 | 65 |
| 50 | Dabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , 2009 , 361, 2342-52 | 59.2 | 1914 |
| 49 | Dabigatran Etxilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , 2009 , 114, 1-1 | 2.2 | 1 |
| 48 | Pulmonary embolism diagnosis: remember the history and physical exam. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 7-8 | 7 | |
| 47 | Do take that break. <i>Harvard Business Review</i> , 2009 , 87, 30, 128 | | |

| | | | |
|----|--|------|-----|
| 46 | Outpatient venous thromboembolism: the importance of optimum prophylaxis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 12-3 | | 3 |
| 45 | Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 35-40 | 5.1 | 26 |
| 44 | Percutaneous mechanical thrombectomy for massive pulmonary embolism: improve safety and efficacy by sharing information. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 70, 807-8 | 2.7 | 8 |
| 43 | Venous thromboembolism risk among hospitalized patients: magnitude of the risk is staggering. <i>American Journal of Hematology</i> , 2007 , 82, 775-6 | 7.1 | 15 |
| 42 | Possible requiem: trial-and-error warfarin. <i>Blood</i> , 2007 , 110, 1404-1405 | 2.2 | |
| 41 | Acute pulmonary embolism: risk stratification. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006 , 35, 153-6 | | 6 |
| 40 | Gastrointestinal complications of dual antiplatelet therapy. <i>Circulation</i> , 2006 , 113, e655-8 | 16.7 | 23 |
| 39 | Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 51-2 | 5.1 | 13 |
| 38 | How chest CT for the diagnosis of pulmonary embolism (PE) has changed my professional life: reflections from a PE doctor. <i>Seminars in Roentgenology</i> , 2005 , 40, 8-10 | 0.8 | 8 |
| 37 | Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro. <i>Archives of Internal Medicine</i> , 2005 , 165, 2197-9; discussion 2204-5 | | 33 |
| 36 | Prevention of venous thromboembolism among hospitalized medical patients. <i>Circulation</i> , 2005 , 111, e1-3 | 16.7 | 38 |
| 35 | Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-2004. A 42-year-old woman with cardiac arrest several weeks after an ankle fracture. <i>New England Journal of Medicine</i> , 2004 , 350, 2281-90 | 59.2 | 7 |
| 34 | Pulmonary embolism after coronary artery bypass grafting. <i>Circulation</i> , 2004 , 109, 2712-5 | 16.7 | 23 |
| 33 | Prevention of recurrent idiopathic venous thromboembolism. <i>Circulation</i> , 2004 , 110, IV20-4 | 16.7 | 15 |
| 32 | A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. <i>American Journal of Cardiology</i> , 2004 , 93, 259-62 | 3 | 385 |
| 31 | Cardiology patient pages. Prevention of deep vein thrombosis and pulmonary embolism. <i>Circulation</i> , 2004 , 110, e445-7 | 16.7 | 27 |
| 30 | Pulmonary embolism. <i>Lancet, The</i> , 2004 , 363, 1295-305 | 40 | 305 |
| 29 | Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. <i>Circulation</i> , 2003 , 108, 2834-8 | 16.7 | 101 |

| | | | |
|----|---|------|-----|
| 28 | DVT Prevention: what is happening in the "real world"?. <i>Seminars in Thrombosis and Hemostasis</i> , 2003 , 29 Suppl 1, 23-31 | 5.3 | 15 |
| 27 | Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. <i>Circulation</i> , 2003 , 108, 2726-9 | 16.7 | 267 |
| 26 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 953-8 | 7 | 7 |
| 25 | Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary Embolism Registry [ICOPER]). <i>American Journal of Cardiology</i> , 2002 , 89, 616-9 | 3 | 14 |
| 24 | Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. <i>Circulation</i> , 2002 , 106, 1436-8 | 16.7 | 56 |
| 23 | Thrombolysis for pulmonary embolism. <i>New England Journal of Medicine</i> , 2002 , 347, 1131-2 | 59.2 | 58 |
| 22 | Cardiology patient pages. Treatment of blood clots. <i>Circulation</i> , 2002 , 106, e138-40 | 16.7 | 11 |
| 21 | Echocardiography in the management of pulmonary embolism. <i>Annals of Internal Medicine</i> , 2002 , 136, 691-700 | 8 | 304 |
| 20 | Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. <i>Chest</i> , 2002 , 122, 1933-7 | 5.3 | 152 |
| 19 | Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1475-8 | 15.1 | 102 |
| 18 | Prophylaxis of Venous Thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001 , 3, 225-235 | 5 | 5 |
| 17 | Epidemiology of pulmonary embolism. <i>Seminars in Vascular Medicine</i> , 2001 , 1, 139-46 | | 14 |
| 16 | Unsolved issues in the treatment of pulmonary embolism. <i>Thrombosis Research</i> , 2001 , 103, V245-55 | 8.2 | 6 |
| 15 | Thrombolysis in Pulmonary Embolism. <i>Circulation</i> , 2001 , 104, 2876-2878 | 16.7 | 34 |
| 14 | Diagnosis of deep venous thrombosis. <i>Clinical Cornerstone</i> , 2000 , 2, 29-37 | | 2 |
| 13 | Diagnosis of pulmonary embolism. <i>Clinical Cornerstone</i> , 2000 , 2, 38-46 | | 5 |
| 12 | Management of deep venous thrombosis and pulmonary embolism. <i>Clinical Cornerstone</i> , 2000 , 2, 47-58; quiz 59-64 | | 4 |
| 11 | The approach to massive pulmonary embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2000 , 21, 555-61 | 3.9 | 3 |

| | | | |
|----|---|------|-----|
| 10 | New onset of venous thromboembolism among hospitalized patients at Brigham and Women Hospital is caused more often by prophylaxis failure than by withholding treatment. <i>Chest</i> , 2000 , 118, 1680-4 | 5.3 | 176 |
| 9 | Deep venous thrombosis: early discharge strategies and outpatient management. <i>Journal of Thrombosis and Thrombolysis</i> , 1999 , 7, 113-22 | 5.1 | 13 |
| 8 | Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 1999 , 8, 139-42 | 5.1 | 58 |
| 7 | Treatment of pulmonary thromboembolism. <i>Internal Medicine</i> , 1999 , 38, 620-5 | 1.1 | 15 |
| 6 | Similarity in Presentation and Response to Thrombolysis Among Women and Men with Pulmonary Embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 95-100 | 5.1 | 5 |
| 5 | Deep Venous Thrombosis: Early Discharge Strategies and Outpatient Management. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 365-374 | 5.1 | |
| 4 | Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. <i>Circulation</i> , 1997 , 95, 577-80 | 16.7 | 78 |
| 3 | Pulmonary embolism thrombolysis: broadening the paradigm for its administration. <i>Circulation</i> , 1997 , 96, 716-8 | 16.7 | 49 |
| 2 | Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. <i>Circulation</i> , 1995 , 92, 2800-216.7 | 16.7 | 158 |
| 1 | Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988 , 38, 303-12 | 4.7 | 5 |